Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents that are constructed by the covalent coupling of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. As a key factor in an ADC, the payload drug dictates its efficacy. At this moment, a large variety of payload drugs have been exploited in ADC and the number is on the rise. To facilitate the unique needs for different ADC development projects, Creative Biolabs has established an advanced ``DrugLnk'' organic synthesis platform with a large collection of payload drugs and linkers in the ``drug module'' and the ``linker module'', respectively. Our scientists are highly experienced in full chemical synthesis, chemical modification, as well as bio-conjugation. We are dedicated to help our clients prepare innovated payload-linker complexes for novel ADC developments.